Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Ardelyx Inc ARDX

Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control... see more

NDAQ:ARDX - Post Discussion

Ardelyx Inc > What's Going On With Ardelyx Stock After Earnings? | Benzing
View:
Post by whytestocks on Feb 23, 2024 7:45pm

What's Going On With Ardelyx Stock After Earnings? | Benzing

Breaking News: $ARDX What's Going On With Ardelyx Stock After Earnings? | BenzingaArdelyx, Inc. (NASDAQ:ARDX) shares are moving Friday after the company reported its fourth-quarter financial results after the bell Thursday. Here&...ARDX - What's Going On With Ardelyx Stock After Earnings? | Benzinga
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities